Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Rudd

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Neural Development|September 13, 2012
Ultrabithorax confers spatial identity in a context-specific manner in the Drosophila postembryonic ventral nervous systemElizabeth C Marin, Katie E Dry, Danielle R Alaimo, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2008
Bismacrocyclic inhibitors of hepatitis C NS3/4a proteaseJohn A McCauley, Michael T Rudd, Kevin T Nguyen, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Nature Communications|February 6, 2021
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activationChuan Hong, Noel J Byrne, Beata Zamlynny, et al.
Nature|April 6, 2017
Structural basis for selectivity and diversity in angiotensin II receptorsHaitao Zhang, Gye Won Han, Alexander Batyuk, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.
Journal of Medicinal Chemistry|June 11, 2014
Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic painShawn J Stachel, John M Sanders, Darrell A Henze, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Neural Development|September 13, 2012
Ultrabithorax confers spatial identity in a context-specific manner in the Drosophila postembryonic ventral nervous systemElizabeth C Marin, Katie E Dry, Danielle R Alaimo, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2008
Bismacrocyclic inhibitors of hepatitis C NS3/4a proteaseJohn A McCauley, Michael T Rudd, Kevin T Nguyen, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Nature Communications|February 6, 2021
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activationChuan Hong, Noel J Byrne, Beata Zamlynny, et al.
Nature|April 6, 2017
Structural basis for selectivity and diversity in angiotensin II receptorsHaitao Zhang, Gye Won Han, Alexander Batyuk, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.
Journal of Medicinal Chemistry|June 11, 2014
Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic painShawn J Stachel, John M Sanders, Darrell A Henze, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Pageof 14